Cargando…

Choroid Plexus Carcinomas With TP53 Germline Mutations: Management and Outcome

BACKGROUND: Choroid plexus carcinomas (CPCs) are rare pediatric tumors commonly associated with Li-Fraumeni syndrome (LFS), which involves a germline mutation of the tumor suppressor gene TP53. MATERIALS AND METHODS: We retrospectively analyzed the corresponding information of 12 cases, including th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yanong, Liu, Hailong, Li, Tandy, Feng, Jin, He, Yanjiao, Chen, Li, Li, Chunde, Qiu, Xiaoguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514937/
https://www.ncbi.nlm.nih.gov/pubmed/34660315
http://dx.doi.org/10.3389/fonc.2021.751784
_version_ 1784583506618220544
author Li, Yanong
Liu, Hailong
Li, Tandy
Feng, Jin
He, Yanjiao
Chen, Li
Li, Chunde
Qiu, Xiaoguang
author_facet Li, Yanong
Liu, Hailong
Li, Tandy
Feng, Jin
He, Yanjiao
Chen, Li
Li, Chunde
Qiu, Xiaoguang
author_sort Li, Yanong
collection PubMed
description BACKGROUND: Choroid plexus carcinomas (CPCs) are rare pediatric tumors commonly associated with Li-Fraumeni syndrome (LFS), which involves a germline mutation of the tumor suppressor gene TP53. MATERIALS AND METHODS: We retrospectively analyzed the corresponding information of 12 cases, including the effects of surgery and radiotherapy and TP53 germline mutations, to analyse the management strategies. Kaplan-Meier curves and the log-rank test were used to evaluate the progression-free survival (PFS). RESULTS: Twelve CPC patients were included, of which TP53 germline mutations were found in eight cases. All patients underwent surgical resection, and six patients received radiotherapy following with operation after initial diagnosis, one patient received radiotherapy following relapse. It was significantly different (P=0.012 and 0.028) that patients with TP53 germline mutation receiving the gross total resection (GTR) without radiotherapy showed survival advantages. Without TP53 germline mutations also showed survival advantages, but there is no statistical significance (P=0.063) CONCLUSIONS: These findings provide evidence for the therapeutic strategy that radiotherapy should not be considered for patients with TP53 germline mutations.
format Online
Article
Text
id pubmed-8514937
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85149372021-10-15 Choroid Plexus Carcinomas With TP53 Germline Mutations: Management and Outcome Li, Yanong Liu, Hailong Li, Tandy Feng, Jin He, Yanjiao Chen, Li Li, Chunde Qiu, Xiaoguang Front Oncol Oncology BACKGROUND: Choroid plexus carcinomas (CPCs) are rare pediatric tumors commonly associated with Li-Fraumeni syndrome (LFS), which involves a germline mutation of the tumor suppressor gene TP53. MATERIALS AND METHODS: We retrospectively analyzed the corresponding information of 12 cases, including the effects of surgery and radiotherapy and TP53 germline mutations, to analyse the management strategies. Kaplan-Meier curves and the log-rank test were used to evaluate the progression-free survival (PFS). RESULTS: Twelve CPC patients were included, of which TP53 germline mutations were found in eight cases. All patients underwent surgical resection, and six patients received radiotherapy following with operation after initial diagnosis, one patient received radiotherapy following relapse. It was significantly different (P=0.012 and 0.028) that patients with TP53 germline mutation receiving the gross total resection (GTR) without radiotherapy showed survival advantages. Without TP53 germline mutations also showed survival advantages, but there is no statistical significance (P=0.063) CONCLUSIONS: These findings provide evidence for the therapeutic strategy that radiotherapy should not be considered for patients with TP53 germline mutations. Frontiers Media S.A. 2021-09-30 /pmc/articles/PMC8514937/ /pubmed/34660315 http://dx.doi.org/10.3389/fonc.2021.751784 Text en Copyright © 2021 Li, Liu, Li, Feng, He, Chen, Li and Qiu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Yanong
Liu, Hailong
Li, Tandy
Feng, Jin
He, Yanjiao
Chen, Li
Li, Chunde
Qiu, Xiaoguang
Choroid Plexus Carcinomas With TP53 Germline Mutations: Management and Outcome
title Choroid Plexus Carcinomas With TP53 Germline Mutations: Management and Outcome
title_full Choroid Plexus Carcinomas With TP53 Germline Mutations: Management and Outcome
title_fullStr Choroid Plexus Carcinomas With TP53 Germline Mutations: Management and Outcome
title_full_unstemmed Choroid Plexus Carcinomas With TP53 Germline Mutations: Management and Outcome
title_short Choroid Plexus Carcinomas With TP53 Germline Mutations: Management and Outcome
title_sort choroid plexus carcinomas with tp53 germline mutations: management and outcome
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514937/
https://www.ncbi.nlm.nih.gov/pubmed/34660315
http://dx.doi.org/10.3389/fonc.2021.751784
work_keys_str_mv AT liyanong choroidplexuscarcinomaswithtp53germlinemutationsmanagementandoutcome
AT liuhailong choroidplexuscarcinomaswithtp53germlinemutationsmanagementandoutcome
AT litandy choroidplexuscarcinomaswithtp53germlinemutationsmanagementandoutcome
AT fengjin choroidplexuscarcinomaswithtp53germlinemutationsmanagementandoutcome
AT heyanjiao choroidplexuscarcinomaswithtp53germlinemutationsmanagementandoutcome
AT chenli choroidplexuscarcinomaswithtp53germlinemutationsmanagementandoutcome
AT lichunde choroidplexuscarcinomaswithtp53germlinemutationsmanagementandoutcome
AT qiuxiaoguang choroidplexuscarcinomaswithtp53germlinemutationsmanagementandoutcome